



Express Mail No.: ED488354956US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kroczek, Richard

Confirmation No.: 9651

Application No.: 10/647,072

Art Unit: 1644

Filed: August 22, 2003

Examiner: Ouspenski, Ilia I.

For: TREATMENT OF IMMUNE DISORDERS WITH ANTIBODIES TO COSTIMULATING POLYPEPTIDE OF T CELLS Attorney Docket No.: 7853-267

DECLARATION OF RICHARD KROCZEK UNDER 37 C.F.R. § 1.132

U.S. Patent and Trademark Office
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

I, RICHARD KROCZEK do declare and state:

1. I am the inventor of the invention described and claimed in the above-identified patent application (the "'072 application").
2. I presently hold the position of Professor of Molecular Immunology at the Robert Koch Institute, Berlin, Germany, the assignee of the above-identified patent application. My *curriculum vitae* is attached hereto as Exhibit 1.
3. I have read and am familiar with the '072 application.
4. The invention claimed in the '072 application is directed to methods of treating immune disorders (claim 77) and autoimmune disorders (claim 78) comprising administering monoclonal antibodies directed against the human 8F4 polypeptide. Since the original filing date of the '072 specification, the 8F4 polypeptide has come to be referred to in the literature as "ICOS" (Inducible T cell Co-Stimulator).
5. Described in paragraphs 6 to 39 below are a number of studies that demonstrate an involvement of the ICOS pathway in a spectrum of immune and autoimmune

disorders. These studies demonstrate that inhibition of the ICOS pathway in accepted animal models for a variety of immune and autoimmune human diseases results in amelioration of the respective diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and rheumatoid arthritis. In addition, for some disease, additional studies are described below that demonstrate the role of ICOS in the pathology of a variety of immune and autoimmune diseases in humans. The studies described below thus corroborate the teachings provided in the application by indicating that successful *in vivo* amelioration of immune disorders and autoimmune disorders can be achieved by administration of anti-ICOS antibodies.

ICOS INVOLVEMENT IN INFLAMMATORY BOWEL DISEASE

6. Inflammatory bowel disease (“IBD”) is a group of inflammatory conditions of the large intestine and, in some cases, the small intestine. The main forms of IBD are Crohn's disease (“CD”) and ulcerative colitis (“UC”), also known as chronic colitis.

7. Several animal models of chronic colitis have been established, including a mouse model involving the adoptive transfer of CD4+CD45RB^{high} native T cells from BALB/c mice to syngeneic SCID mice. In this murine model, the recipient mice develop symptoms similar to IBD (Totsuka *et al.*, 2003, *Gastroenterology* 124:410-421 (“Totsuka”) at page 410). In this murine model, administration of anti-ICOS antibodies to the SCID recipient mice ameliorated chronic colitis both during the establishment and following onset of the disease (see Totsuka at Abstract, under “Results” and page 413, right column). The observations of Totsuka, among other studies in the literature, led Kanai *et al.*, 2002, *J. Gastroenterol.* 37[Suppl. XIV]:78-81 to propose ICOS as a therapeutic target for human IBD patients (see, *e.g.*, Kanai at Abstract).

8. Sato *et al.*, 2004, *Gastroenterology* 126:829-39 (“Sato”) analyzed the expression and role of ICOS in UC and CD in human patients. Sato demonstrated that ICOS-

expressing CD4+ lamina propria T cells (“LPTC”) were significantly increased in the inflammatory mucosa patients with active, but not inactive, UC and CD as compared to a normal control (see Sato at Abstract; page 832, right column; and page 836, right column). ICOS stimulation also enhanced production of certain cytokines by UD and CD (see Figure 6 and page 836, right column). Because the ICOS upregulation observed by Sato was limited to the inflammatory sites of IBD, ICOS is proposed to be an “ideal” therapeutic target for IBD (Sato at Abstract; page 836, right column; and page 838, right column).

9. Taken together, Totsuka, Kanai and Sato strongly indicate that: a) ICOS participates in the pathogenesis of IBD in humans; and b) treatment of IBD can be achieved by inhibiting the ICOS pathway, such as by administration anti-ICOS antibodies, in patients suffering from IBD.

ICOS INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE.

10. Systemic lupus erythematosus (“SLE”) is a chronic inflammatory disease whose patients exhibit different immunological abnormalities, including the production of autoimmune antibodies, lack of T- and B-cell regulation, and defective clearance of autoantigens and immune complexes. SLE has manifestations in the kidneys, central nervous system, and skin (see, *e.g.*, the backgrounds of (Hutloff *et al.*, 2004, Arthritis and Rheumatism 50(1):3211-3220 (“Hutloff”); Yang *et al.*, 2005, Rheumatology e-publication doi:10.193/rheumatology/keh724 (“Yang”); and Iwai *et al.*, 2003, J. Immunol. 171:2848-54 (“Iwai”).

11. Iwai studied the role of the ICOS pathway in a mouse model of SLE, murine lupus nephritis, which reflects the renal pathology of SLE. SLE and murine lupus nephritis both are characterized in the deposition of autoimmune antibodies in the kidneys. Iwai studied the expression of ICOS on T cells from NZB/W F₁ mice, which spontaneously develop murine lupus nephritis, before and after onset of the disease. Iwai observed the

ICOS expression on T cells from splenocytes and on peripheral blood lymphocytes increase with age, and occurs on almost all T cells by the onset of the disease (Iwai at 2849, right paragraph). Inhibition of the ICOS pathway by use of an antibody against the ICOS ligand ("ICOS-L"), B7RP-1 (also known as B7h), prevented disease onset and, following cessation of treatment, some symptoms of the disease developed, but with a markedly improved disease course (Iwai at page 2850). In addition, treatment of mice with the anti-B7RP-1 antibody following onset of the disease improved the symptoms of the disease and survival rate (Iwai at pages 2851-52)¹

12. Hutloff and Yang, which document the involvement of ICOS in SLE in humans, further confirm the role of ICOS in the pathology of the disease. Hutloff is a publication of a study performed in my laboratory to determine the expression levels of ICOS in patients with SLE. The data showed that ICOS is expressed in CD4+ and CD8+ T cells and a concomitant downregulation of ICOS Ligand (ICOS-L) on B cells of such patients. Our study also indicated that the downregulation of ICOS-L is a result of the interaction of ICOS+ T cells with the B cells. In addition, we observed clusters of B cells and plasma cells in close contact with ICOS + T cells in the kidneys of SLE patients. These data strongly indicate that ICOS is an important driving force in the pathogenesis of SLE.

13. Similar results to those of the Hutloff publication were obtained by Yang. In addition, Yang showed that inhibition of the ICOS pathway in peripheral blood mononuclear cells from patients with SLE inhibited the production of pathological anti-DNA antibodies (Yang at pages 7-8 and Figure 4). These data further confirm that the activation of the ICOS pathway in SLE patients is involved in the pathology of SLE.

¹ Although Iwai did not see any therapeutic benefits of an anti-ICOS antibody, further analysis of the anti-ICOS antibody employed in Iwai's studies demonstrated that it was an agonistic, rather than an antagonistic, antibody (Iwai at page 2852, right column).

14. Taken together, Iwai, Hutloff and Yang strongly indicate that: a) ICOS participates in the pathogenesis of SLE in humans; and b) treatment of SLE can be achieved by inhibiting the ICOS pathway, such as by administration of anti-ICOS antibodies, in patients suffering from SLE.

ICOS INVOLVEMENT IN RHEUMATOID ARTHRITIS.

15. Rheumatoid arthritis (“RA”) is a chronic inflammatory joint disease (see background sections of Okamoto *et al.*, 2003, J. Rheumatology 30:1157-63 (“Okamoto”); Nurieva *et al.*, 2003, J. Clin. Invest. 111:701-06 (“Nurieva”); and Iwai *et al.*, 2002, J. Immunol. 169:4332-4339 (“Iwai 2”). Collagen-induced arthritis (“CIA”) is the most widely used mouse model for RA (see, *e.g.*, Nurieva at Introduction).

16. ICOS expression is observed in inflammatory tissue involved in CIA, such as synovium and lymph nodes (Iwai 2 at page 4335). Blocking the ICOS pathway using an antibody against B7RP-1 beginning at disease induction “significantly ameliorated the clinical manifestations of CIA in a dose dependent manner” (Iwai 2 at page 4334, left column). Furthermore, blocking the ICOS pathway after onset of the disease was also “effective at reducing the clinical arthritis scores” (*i.e.*, effective at reducing severity of the disease) (Iwai 2 at page 4334, right column). This study demonstrates a therapeutic potential for blocking the ICOS pathway, for example by using an anti-ICOS antibody, in RA.

17. The role of ICOS in CIA was further confirmed by Nurieva’s study² analyzing the ability of ICOS knockout mice to develop CIA. Nurieva observed that the ICOS knockout mice were completely resistant to CIA (Nurieva at page 703). This study

² Although Nurieva was subsequently retracted (J. Clin. Invest. 112:1597), the reason of the retraction was that the study had not been performed with the permission of the University of Washington Institutional Animal Care and Usage Committee; however, the data in the publication are still valid.

corroborates the conclusion drawn from Iwai 2 that blocking the ICOS pathway, for example by using an anti-ICOS antibody, has a therapeutic potential for RA.

18. Okamoto confirms the role of ICOS in the pathology of arthritis in humans. Specifically, Okamoto is a study of ICOS (also referred to by Okamoto as H4) expression and function in human rheumatoid arthritis, and demonstrates that ICOS is overexpressed in the mononuclear cells of peripheral blood of RA patients as compared to healthy individuals, and also in synovial fluid of RA patients (Okamoto at page 1161, right column). The ICOS ligand B7RP-1 is also expressed in synovial tissues of patients (Okamoto at page 1161, right column). Based on these results and others, Okamoto suggests that the expression of ligand in synovial tissue activates ICOS in synovial fluid T cells, resulting in induction of proinflammatory cytokine expression and RA disease pathology (Okamoto at page 1161, right column and page 1162).

19. Taken together, Iwai 2, Nurieva and Okamoto demonstrate that: a) ICOS participates in the pathogenesis of RA in humans; and b) amelioration of RA symptoms in humans can be achieved by blocking the ICOS pathway, such as by administration of anti-ICOS antibodies.

ICOS INVOLVEMENT IN AUTOIMMUNE MYOCARDITIS

20. Myocarditis is the inflammation of the myocardium, the muscular part of the heart. The origins of myocarditis are often autoimmune reactions to cardiac myosin (see, *e.g.*, Matsui *et al.*, 2003, Human Gene Therapy 14:521-32 (“Matsui”) at Introduction and Futamatsu *et al.*, 2003, Cardiovascular Research 59:95-104 (“Futamatsu”) at Introduction).

21. Experimental autoimmune myocarditis (“EAM”) is a rat model of myocarditis that involves immunization of rats with cardiac myosin (see Introductions of Matsui and Futamatsu). There are two phases of EAM: an antigen priming phase (days 0-14) and an immune response phase (days 14-21) (see Futamatsu at background). Matsui and Futamatsu

used different approaches to block the ICOS pathway in EAM: Matsui employed an adenoviral expression vector of soluble ICOS (which is a competitive inhibitor of the binding of native ICOS to its ligand) and Futamatsu employed an anti-ICOS antibody and soluble ICOS ligand (which is a competitive inhibitor of the binding of native ICOS ligand to ICOS).

22. In Matsui's study, increased expression of ICOS and its ligand in lymphoid tissue of EAM rats was observed (see, *e.g.*, Figure 2). Administration of the soluble ICOS adenoviral vector resulting in expression during the first phase of EAM had little therapeutic benefit; however, administration of the vector resulting in expression during the second phase of EAM ameliorated the symptoms of the disease (see, *e.g.*, Table 1 and Figure 5) and improved the survival rate of the animals (see Table 2). Matsui concludes that blockade of the ICOS pathway had therapeutic potential for ongoing autoimmune myocarditis (Matsui at Abstract and Overview Summary).

23. Futamatsu observed similar results. ICOS was detected on myocardial inflammatory cells (page 98, left column). Blockade of the ICOS pathway in the first phase of EAM also had little therapeutic benefit while treatment during the second phase improved disease symptoms (see, *e.g.*, Figures 3 and 4). Futamatsu concludes that blockade of the ICOS pathway may have potential therapy for myocarditis (see Abstract and page 103, right column).

ICOS INVOLVEMENT IN MYASTHENIA GRAVIS

24. Myasthenia gravis is a chronic autoimmune neuromuscular disease, characterized by varying degrees of weakness of the skeletal muscles, that results from autoantibodies to the nicotinic acetylcholine receptors ("AChRs) of the neuromuscular junction (see, *e.g.*, Scott *et al.*, 2004, J. Neuroimmunology 153:16-25 ("Scott") at Introduction).

25. Scott studied the role of ICOS in a mouse model of myasthenia gravis, experimental autoimmune myasthenia gravis (“EAMG”), by analyzing the development of the disease in ICOS knockout mice. EAMG is induced by immunization with AChR protein. Unlike normal mice, which develop symptoms that accurately mimic the pathogenesis of myasthenia gravis in response to immunization with AChR protein (Scott at Introduction), ICOS knockout mice were highly resistant to clinical experimental autoimmune myasthenia gravis (Scott at Abstract). Scott’s results strongly suggest a therapeutic potential for the treatment of myasthenia gravis in humans by blocking the ICOS pathway, for example by use of an anti-ICOS antibody.

ICOS INVOLVEMENT IN AUTOIMMUNE UVEORETINITIS

26. Uveitis is inflammation inside the eye, specifically affecting one or more of the three parts of the eye that make up the uvea: the iris, the ciliary body, and the choroid.

27. Usui *et al.*, 2006, Eur. J. Immunol. 36:3071-81 (“Usui”) studied the role of ICOS in a mouse model of uveitis, experimental autoimmune uveoretinitis (“EAU”), by blocking the ICOS pathway at different stages of the disease. EAU is induced by immunization with interphotoreceptor retinoid-binding protein (“IRBP”). Normal mice develop a histopathology that accurately mimic the pathogenesis of myasthenia gravis in response to immunization with IRBP (Usui at page 3072). Following induction of EAU in mice, ICOS is expressed on ocular infiltrating CD4+ T cells and expression of its ligand B7RP-1 is upregulated in ocular tissue (Usui at Figures 1 and 2). Disease progression was limited in ICOS knockout mice (Figure 3D-3F), and blocking the ICOS pathway with an antibody against B7RP-1 ameliorated the symptoms of the disease (Figure 3A-3C). Blockade of the pathway was effective in the second (effector) stage of EAU but not the first (induction) stage. Usui’s results strongly suggest a therapeutic potential for the treatment of uveitis in humans by blocking the ICOS pathway, for example using anti-ICOS antibodies.

ICOS INVOLVEMENT IN ATOPIC DERMATITIS

28. Atopic dermatitis (“AD”), also called eczema, is a highly prevalent chronic inflammatory skin disease characterized by inflammatory cell infiltration in the skin (Chen *et al.*, 2004, Clinical and Experimental Immunology 139:189-201 (“Chen”) at Summary and Introduction).

29. Chen employed a transgenic IL-4 mouse model, in which the mice are characterized by spontaneous development of chronic inflammatory symptoms closely resembling human AD, to analyze of the role of ICOS at different stages of the disease: (1) prior to onset, (2) early or acute lesion, and (3) late or chronic lesion. Chen observed the expression of ICOS increase in secondary lymphoid organs during disease progression (see Figure 1), suggesting a role for ICOS in disease progression and implicating ICOS as a potential therapeutic target for AD.

ICOS INVOLVEMENT IN MULTIPLE SCLEROSIS

30. Multiple sclerosis is a chronic, inflammatory, demyelinating, autoimmune disease that affects the central nervous system.

31. Experimental allergic encephalomyelitis (EAE) is the primary recognized animal model of multiple sclerosis. EAE is initiated by immunizing susceptible strains of mice with specific myelin proteins such as proteolipid protein peptide (PLP) 139-151. The immune response to the myelin antigens can be divided into afferent and efferent phases. During the afferent phase, myelin antigens are “processed” by antigen presenting cells (APCs) in regional lymph nodes and presented in the context of major histocompatibility class II (MHC II) molecules to naïve myelin-specific CD4+ T cells. The interaction of the MHC II molecule with the T cell receptor (TCR) sends an activation signal to the cell, ultimately resulting in differentiation into an encephalitogenic effector T cell. During the efferent phase of the disease, the encephalitogenic T cells traffic to the brain and are further

activated in situ through the TCR to mediate disease (see, *e.g.*, Rottman *et al.*, 2001, Nat Immunol. 2(7):605-11 (“Rottman”) at background).

32. In Rottman, mice in which experimental EAE was induced were treated with a blocking anti-ICOS antibody either during antigen priming (days 1-10) or during the efferent immune response to PLP (days 9-20). Although blockade of the ICOS pathway during antigen priming (1-10 days after immunization) exacerbated disease, ICOS blockade during the efferent immune response (9-20 days after immunization) abrogated disease (see Rottman at Abstract).

33. In my opinion, although the timing of treatment is important to maximize its therapeutic efficacy, blocking the ICOS pathway using anti-ICOS antibodies is a promising clinical approach for treatment of multiple sclerosis.

ICOS INVOLVEMENT IN ORGAN TRANSPLANT REJECTION

34. Several animal studies indicate that blocking the ICOS pathway, for example, using anti-ICOS antibodies or soluble ICOS ligand, results in improved survival of organ transplants.

35. For example, Ozkaynak *et al.*, 2001, Nat. Immunol. 2(7):591-96 is one study that describes the inhibition of the ICOS pathway by an anti-ICOS monoclonal antibody or an ICOS polypeptide in the context of organ transplant rejection. The data presented in Ozkaynak demonstrate that the administration of an anti-ICOS antibody or a soluble ICOS polypeptide to an organ transplant recipient leads to inhibition of organ transplant rejection and prolongation of graft survival from approximately one week to almost three weeks (Figure 2). Similar prolongation of graft survival was observed in ICOS deficient mice, further evidencing a role for ICOS in rejection of the transplant.

36. Similarly, a study by Nakamura *et al.*, 2003, Transplantation 75(8):1115-8 (“Nakamura”) demonstrates that treatment of a mouse recipient of an islet allograft with an

anti-ICOS antibody prolonged islet allograft survival. Moreover, when the anti-ICOS antibody treatment was administered as part of a regimen further including an immunosuppressive agent, not only was graft survival prolonged, but the regimen also increased the survival of the experimental animals at 90-days post transplant to 50%, from 0% in untreated animals and 11% in animals treated with a comparable dosage of immunosuppressive reagent. These data lead the Nakamura authors to conclude that “ICOS has an essential role in rejection of intrahepatic islet allografts and the blockade of ICOS interaction might be a novel approach for preventing islet allograft rejection” (Nakamura at Abstract).

37. Harada *et al.*, 2003, J. Clin. Invest. 112(2):234-43 (“Harada”), describes experiments testing the effect of blocking the ICOS pathway at different times following transplantation of cardiac allografts (early treatment and delayed treatment) in experimental animals with different immune make ups (recipient animals whose minor histocompatibility antigen matched that of the donor and recipient animals whose minor histocompatibility antigen mismatched that of the donor). Harada demonstrates a beneficial effect of administration of disrupting the ICOS pathways in three out of the four experimental set ups described: both early and delayed treatment in the minor histocompatibility mismatched animals, and in the delayed treatment in the minor histocompatibility matched animals (see Figure 1 on page 236 of Harada). In one group, the histocompatibility matched animals receiving an early anti-ICOS antibody treatment, the early treatment accelerated graft rejection (Figure 1). The authors of Harada conclude that, overall, blocking the ICOS pathway is an effective means of prolongation of graft survival (see, *e.g.*, the last paragraph of the Discussion on page 242 of Harada), although the timing of treatment is important to maximize its therapeutic efficacy.

38. Thus, despite the limited circumstances under which blocking the ICOS pathway accelerated graft rejection, it is my belief that blocking the ICOS pathway using anti-ICOS antibodies is a promising clinical approach for treatment of organ transplant rejection.

ICOS INVOLVEMENT IN ASTHMA

39. I have previously described experiments evidencing the role of ICOS in asthmatic disorders by way of a declaration in connection with U.S. Patent Application No. 09/972,524 (now U.S. Patent No. 7,125,551). Based on the evidence presented in that Declaration, attached hereto as Exhibit 21, I concluded that “a) ICOS participates in the pathogenesis of allergic asthma in human; and b) amelioration of asthma symptoms in human can be achieved by administration of antibodies that recognize the ICOS polypeptide.” Exhibit 21 at ¶ 14.

CONCLUSION


40. The studies described herein implicate ICOS in a wide spectrum of immune and autoimmune diseases. The animal models of disease employed in the studies are the best approximations of the corresponding human diseases known to the scientific community and are used by the pharmaceutical industry in preclinical studies of clinical candidates. The data obtained from the studies described above strongly indicate that treatment of a number of such diseases can be achieved by inhibiting the ICOS pathway, for example by use of an anti-ICOS antibody. Indeed, on the basis of studies such as those described herein, MedImmune Inc. has licensed an anti-ICOS antibody from Japan Tobacco Inc. for development as an anti-inflammatory therapeutic for autoimmune disorders SLE and RA (see, *e.g.*, Exhibit 22, Bioworld Today December 29, 2006 at pages 1-2). It is also my opinion that most, if not all, inhibitory anti-ICOS antibodies will exhibit some efficacy towards treatment of such diseases, and that optimization of any given antibody for clinical use (*e.g.*, by chimerization

or humanization and/or improvement of the binding kinetics by mutagenesis of the antibodies' complementarity determining regions) could have been performed as of September 1997 using standard methodologies.

41. I declare further that all statements made in this Declaration of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated:

May 2, 2007


Richard Krocze

Attachments:

- Exhibit 1. *Curriculum vitae* of Richard Krocze, M.D.
- Exhibit 2. Totsuka *et al.*, 2003, *Gastroenterology* 124:410-421
- Exhibit 3. Kanai *et al.*, 2002, *J. Gastroenterol.* 37[Suppl. XIV]:78-81
- Exhibit 4. Sato *et al.*, 2004, *Gastroenterology* 126:829-39
- Exhibit 5. Hutloff *et al.*, 2004, *Arthritis and Rheumatism* 50(10):3211-3220
- Exhibit 6. Yang *et al.*, 2005, *Rheumatology* e-publication
doi:10.193/rheumatology/keh724
- Exhibit 7. Iwai *et al.*, 2003, *J. Immunol.* 171:2848-54
- Exhibit 8. Okamoto *et al.*, 2003, *J. Rheumatology* 30:1157-63
- Exhibit 9. Nurieva *et al.*, 2003, *J. Clin. Invest.* 111:701-06
- Exhibit 10. Iwai *et al.*, 2002, *J. Immunol.* 169:4332-39
- Exhibit 11. Nurieva *et al.*, 2003, *J. Clin. Invest.* 112:1597

- Exhibit 12. Matsui *et al.*, 2003, Human Gene Therapy 14:521-32
- Exhibit 13. Futamatsu *et al.*, 2003, Cardiovascular Research 59:95-104
- Exhibit 14. Scott *et al.*, 2004, J. Neuroimmunology 153:16-25
- Exhibit 15. Usui *et al.*, 2006, Eur. J. Immunol. 36:3071-81
- Exhibit 16. Chen *et al.*, 2004, Clinical and Experimental Immunology 139:189-201
- Exhibit 17. Rottman *et al.*, 2001, Nat. Immunol. 2(7):605-11
- Exhibit 18. Ozkaynak *et al.*, 2001, Nat. Immunol. 2(7):591-96
- Exhibit 19. Nakamura *et al.*, 2003, Transplantation 75(8):1115-8
- Exhibit 20. Harada *et al.*, 2003, J. Clin. Invest. 112(2):234-43
- Exhibit 21. Krocze Rule 132 Declaration in connection with U.S. Patent Application No. 09/972,524.
- Exhibit 22. Bioworld Today, December 29, 2006 edition.

CURRICULUM VITAE

Name: Richard Kroczeck, M.D.

Occupation: Professor, Molecular Immunology
Robert Koch-Institute
Nordufer 20, 13353 Berlin, Germany

Phone: (+49) 30 4547-2450
Fax: (+49) 30 4547-2603
e-mail: kroczeck@rki.de

Personal Information: born November 3, 1952 in Orlau
Nationality: German

Education and Training:

1964 - 1973	Attending the Hans-Leinberger-Gymnasium in Landshut, Germany; graduated first in the class of 1973
1973 - 1976	Pre-clinical studies at the University of Kiel
1976 - 1977	Medical School, University of Bonn
1977 - 1978	Westminster Hospital Medical School, London, supported by a grant from the Deutscher Akademischer Austauschdienst
1978 - 1981	Continuation of clinical studies at the University of Bonn
1981	Final Medical Exam ("Staatsexamen"); Doctoral thesis; Medical License
1981 - 1983	Residency in Pediatrics at the Munich University Children's Hospital
1983	American Medical Exam (VQE)
1984 - 1986	Postdoctoral Fellow in Immunology with Dr. Ethan Shevach in the Laboratory of Allergy and Infectious Diseases, NIH, USA. Supported by a grant from the Deutsche Forschungsgemeinschaft. Research topics: Role of Thy-1 in T-cell activation, action of cyclosporin A
1986	Research fellow of the Fogarty Foundation

1986 - 1987

Postdoctoral fellow at the Max-Planck-Institute for Immunobiology in Freiburg

Employment:

1987 - 1992

Head of a research group at the Max-Planck-Society Research Unit for Immunology in Erlangen, Germany

1990

Habilitation at the University of Erlangen; faculty member of the university

1997

Professor, University of Erlangen

1993 -

Head, Molecular Immunology, Robert Koch-Institute, Berlin

1999

Offered chair in immunology at the Free University of Berlin (not accepted)

Current research:

Molecular mechanisms of early T cell activation, T cell/B cell cooperation, T cell/monocyte cooperation, T cell/dendritic cell cooperation focus on the function of CD40 Ligand, ATAC and ICOS molecules in vitro and in vivo

Professional and scientific activities:

Member of the German Society for Immunology.

Reviewer for various scientific journals (European Journal of Immunology, Journal of Immunology, European Journal of Biochemistry, Blood, Journal of Clinical Investigation, Nature Medicine).

Reviewer for various scientific societies and funding agencies.

Honors:

Science prize of the SmithKline Beecham Foundation 1999.

PUBLIKATIONSVERZEICHNIS

1. KroczeK RA, Däumling S, Belohradsky BH.
Kawasaki-Syndrom. 4 Todesfälle in der Bundesrepublik.
Diagnose, Therapie und Prognose der kardialen
Komplikationen.
Pädiatrische Praxis 28 (1983) 491-495
2. Mezger J, KroczeK RA, Belohradsky BH, Remberger K.
Das Kawasaki-Syndrom.
Medizinische Welt 34 (1983) 1085-1090
3. KroczeK RA.
Congenital chyloperitoneum: Direct comparison of medium-
chain triglyceride treatment with total parenteral
nutrition.
European Journal of Pediatrics 144 (1985) 77-79
4. KroczeK RA, Mühlbauer W, Zimmermann S.
Cloverleaf skull associated with Pfeiffer-syndrome:
pathology and management.
European Journal of Pediatrics 145 (1986) 442-445
5. Gunter KC, KroczeK RA, Shevach EM, Germain RN.
Functional expression of the murine Thy-1.2 gene in
transfected human T cells.
Journal of Experimental Medicine 163 (1986) 285-300
6. KroczeK RA, Gunter KC, Seligmann B, Shevach EM.
Induction of T cell activation by monoclonal anti-Thy-1
antibodies.
Journal of Immunology 136 (1986) 4379-4384
7. KroczeK RA, Gunter KC, Germain RN, Shevach EM.
Thy-1 functions as a signal transduction molecule in
T-lymphocytes and transfected B-lymphocytes.
Nature 322 (1986) 181-184
8. Malek TR, Ortega G, Chan C, KroczeK RA, Shevach EM.
Role of Ly-6 in lymphocyte activation. II. Induction of
T cell activation by monoclonal anti-Ly-6 antibodies.
Journal of Experimental Medicine 164 (1986) 709-722
9. Gunter KC, Germain RN, KroczeK RA, Saito T, Yokoyama WM,
Chan C, Weiss A, Shevach EM.
Thy-1-mediated T-cell activation requires co-expression of
CD3/Ti complex.
Nature 326 (1987) 505-507
10. KroczeK RA, Black CDV, Barbet J, Edison LJ, Shevach EM.
Induction of IL-2 receptor expression in vivo: Response to
allogeneic cells.
Transplantation 44 (1987) 547-553

11. KroczeK RA, Black CDV, Barbet J, Shevach EM.
Mechanism of action of Cyclosporin A in vivo. Cyclosporin A fails to inhibit T lymphocyte activation in response to alloantigens.
Journal of Immunology 139 (1987) 3597-3603
12. Black CDV, KroczeK RA, Barbet J, Weinstein J, Shevach EM.
Induction of IL-2 receptor expression in vivo: Response to Concanavalin A.
Cellular Immunology 111 (1988) 420-432
13. KroczeK RA.
Immediate visualization of blotted RNA in Northern analysis.
Nucleic Acids Research 17 (1989) 9497
14. KroczeK RA, Siebert E.
Optimization of Northern analysis by vacuum-blotting, RNA-transfer visualization and UV-fixation.
Analytical Biochemistry 184 (1990) 90-95
15. Potocnik AJ, Kinne R, Menninger H, Zacher J, Emmrich F, KroczeK RA.
Expression of activation antigens on T cells in rheumatoid arthritis patients.
Scandinavian Journal of Immunology 31 (1990) 213-224
16. Potocnik AJ, Menninger H, Yang SY, Pirner K, Krause, A, Burmester GR, Bröker BM, Hept P, Weseloh G, Michels H, Truckenbrodt H, Emmrich F, KroczeK RA.
Expression of the CD2 activation epitope T11-3 (CD2R) on T-cells in rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, and lyme disease: phenotypic and functional analysis.
Scandinavian Journal of Immunology 34 (1991) 351-358
17. Korthäuer U, Hennerkes B, Menninger H, Mages HW, Zacher J, Potocnik AJ, KroczeK RA.
Oligoclonal T-cells in rheumatoid arthritis: identification strategy and molecular characterization of a clonal T-cell receptor.
Scandinavian Journal of Immunology 36 (1992) 855-863
18. Graf D, Korthäuer U, Mages HW, Senger G, KroczeK RA.
Cloning of TRAP, a ligand for CD40 on human T cells.
European Journal of Immunology 22 (1992) 3191-3194
19. Mages HW, Stamminger T, Rilke O, Bravo R, KroczeK RA.
Expression of PILOT, a putative transcription factor, requires in T-cells two signals and is cyclosporin A sensitive.
International Immunology 5 (1993) 63-67

20. Kroczek RA.
Southern and Northern analysis.
Journal of Chromatography 618 (1993) 133-145
21. Korthäuer U, Graf D, Mages HW, Brière F, Padayachee M,
Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek
RA.
Defective expression of T-cell CD40 ligand causes X-linked
immunodeficiency with hyper-IgM.
Nature 361 (1993) 539-541
22. Bröker BM, Korthäuer U, Heppt P, Weseloh G, de la Camp R,
Kroczek RA, Emmrich F.
Biased T cell receptor V gene usage in rheumatoid
arthritis. Oligoclonal expansion of T cells expressing V β 2
genes in synovial fluid but not in peripheral blood.
Arthritis and Rheumatism 36 (1993) 1234-1243
23. Zimmermann S, Becker-Perez I, Beuscher HU, Kroczek RA,
Roellinghoff M, Solbach W.
Leishmania major parasites share an epitope with the murine
CD3-T cell receptor complex.
European Journal of Immunology 24 (1994) 503-507
24. Villa A, Notarangelo LD, DiSanto JP, Macchi PP, Strina D,
Frattini A, Lucchini F, Patrosso CM, Giliani S, Mantuano E,
Agosti S, Nocera G, Kroczek RA, Fischer A, Ugazio AG, de
Saint Basile G, Vezzoni P.
Organization of the human CD40L gene - implications for
molecular defects in X-chromosome-linked hyper-IgM syndrome
and prenatal diagnosis.
Proceedings of the National Academy of Sciences 91 (1994)
2110-2114
25. Brugnoni D, Airo P, Graf D, Marconi M, Lebowitz M, Plebani
A, Giliani S, Malacarne F, Cattaneo R, Ugazio AG, Albertini
A, Kroczek RA, Notarangelo LD.
Ineffective expression of CD40 ligand on cord blood T cells
may contribute to poor immunoglobulin production in the
newborn.
European Journal of Immunology 24 (1994) 1919-1924
26. Kroczek RA, Graf D, Brugnoni D, Giliani S, Korthäuer U,
Ugazio A, Senger G, Mages HW, Villa A, Notarangelo LD.
Defective expression of CD40 ligand on T cells causes
"X-linked immunodeficiency with hyper-IgM (HIGM1)".
Immunological Reviews 138 (1994) 39-59
27. Callard RE, Smith SH, Herbert J, Morgan G, Padayachee M,
Lederman S, Chess L, Kroczek RA, Fanslow WC, Armitage RJ.
CD40 ligand (CD40L) expression and B cell function in
agammaglobulinemia with normal or elevated levels of IgM
(HIM). Comparison of X-linked, autosomal recessive and
non-X linked forms of the disease, and obligate carriers.
Journal of Immunology 153 (1994) 3295-3306

28. Mages HW, Rilke O, Bravo R, Senger G, KroczeK RA.
NOT, a human immediate-early response gene closely related
to the steroid/thyroid hormone receptor NAK1/TR3.
Molecular Endocrinology 8 (1994) 1583-1591
29. Durandy A, de Saint Basile G, Lisowska-GrosPierre B,
Gauchat JF, Forveille M, KroczeK RA, Bonnefoy JY, Fischer
A.
Undetectable CD40 ligand expression on T cells and low B
cell responses to CD40 binding agonists in human newborns.
Journal of Immunology 154 (1995) 1560-1568
30. Kinne RW, Boehm S, Iftner T, Aigner T, Vornehm S, Weseloh
G, Bravo R, Emmrich F, KroczeK RA.
Synovial fibroblast-like cells strongly express Jun-B and
C-Fos proto-oncogenes in rheumatoid- and osteoarthritis.
Scandinavian Journal of Rheumatology S 101 (1995) 121-125
31. Müller S, Dorner B, Korthäuer U, Mages HW, D'Apuzzo M,
Senger G, KroczeK RA.
Cloning of ATAC, an activation-induced, chemokine-related
molecule exclusively expressed in CD8⁺ T lymphocytes.
European Journal of Immunology 25 (1995) 1744-1748
32. Graf D, Müller S, Korthäuer U, van Kooten C, Weise C,
KroczeK RA.
A soluble form of TRAP (CD40 ligand) is rapidly released
after T cell activation.
European Journal of Immunology 25 (1995) 1749-1754
33. Ludewig B, Graf D, Gelderblom HR, Becker Y, KroczeK RA,
Pauli G.
Spontaneous apoptosis of dendritic cells is efficiently
inhibited by TRAP (CD40-ligand) and TNF- α , but strongly
enhanced by interleukin-10.
European Journal of Immunology 25 (1995) 1943-1950
34. Notarangelo LD, Peitsch MC, KroczeK RA et al.
CD40Lbase: a database of CD40L gene mutations causing
X-linked hyper-IgM syndrome.
Immunology Today 17 (1996) 511-516
35. Ruggiero G, Caceres EM, Voordouw A, Noteboom E, Graf D,
KroczeK RA, Spits H.
CD40 expressed on thymic epithelial cells provides
costimulation for proliferation but not for apoptosis of
human thymocytes.
Journal of Immunology 156 (1996) 3737-3746
36. Brugnani D, Airo P, Graf D, Marconi M, Molinari C, Braga D,
Malacarne F, Soresina A, Ugazio AG, Cattaneo R, KroczeK RA,
Notarangelo LD.
Ontogeny of CD40 ligand expression by activated peripheral
blood lymphocytes in humans.

37. Nasert S, Burtchen N, Kussebi F, Millner M, KroczeK R, Jung T, Schwinzer R, Wahn U, Renz H.
Stimulation of IgE and IgA production by CD45 RA T helper cells in atopic patients.
Journal of Immunology 157 (1996) 441-448
38. Feske S, Müller JM, Graf D, KroczeK RA, Dräger R, Niemeyer C, Baeuerle PA, Peter HH, Schlesier M.
Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings.
European Journal of Immunology 26 (1996) 2119-2126
39. Ludewig B, Henn V, Schröder, JM, Graf D, KroczeK RA.
Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4⁺CD45RA⁺ T cells with dendritic cells.
European Journal of Immunology 26 (1996) 3137-3143
40. Schultz A, Greiner A, Nenninger R, Schoemig D, Wilisch A, Oswald E, KroczeK RA, Schalkef B, Mueller-Hermelink HK, Marx A.
CD40 als Vermittler von Proliferation in normalem und neoplastischem Thymusepithel.
Verhandlungen der Deutschen Gesellschaft für Pathologie 80 (1996) 250-255
41. Dorner B, Müller S, Entschladen F, Schröder JM, Franke P, Kraft R, Friedl P, Clark-Lewis I, KroczeK RA.
Purification, structural analysis and function of natural ATAC, a cytokine expressed in CD8⁺ T cells.
Journal of Biological Chemistry 272 (1997) 8817-8823
42. Hermes B, Worm M, Nowak F, KroczeK RA, Stein H, Henz BM.
Upregulation of CD40 and CD40-ligand expression in IgE-associated cutaneous diseases.
Acta Dermatologica Veneorologica 77 (1997) 441-445
43. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, KroczeK RA.
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.
Nature 391 (1998) 591-594
44. Slupsky JR, Kalbas M, Willuweit A, Henn V, KroczeK RA, Müller-Berghaus G.
Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40.
Thrombosis and Haemostasis 80 (1998) 1008-1014
45. Mages HW, Baag R, Steiner B, KroczeK RA.
Utilization of an NF-ATp binding promoter element for EGR3 expression in T cells but not fibroblasts provides a

molecular model for the lymphoid cell-specific effect of Cyclosporin A.

Molecular and Cellular Biology 18 (1998) 7157-7165

46. Greiner A, Knoerr C, Qin Y, Schultz A, Marx A, KroczeK RA, Mueller-Hermelink HK.
CD40 ligand and autoantigen are involved in the pathogenesis of low-grade B-cell lymphomas of mucosa-associated lymphoid tissue.
Developmental Immunology, 6 (1998) 187-195
47. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, KroczeK RA.
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.
Nature 397 (1999) 263-266
48. Mages HW, Hutloff A, Heuck C, Büchner K, Himmelbauer H, Oliveri F, KroczeK RA.
Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand.
European Journal of Immunology 30 (2000) 1040-1047
49. Rengarajan J, Mittelstadt PR, Mages HW, Gerth AJ, KroczeK RA, Ashwell JD, Glimcher LH.
Sequential involvement of NFAT and Egr transcription factors in FasL regulation.
Immunity 12 (2000) 293-300
50. Lienenlücke B, Germann T, KroczeK RA, Hecker M.
CD154 stimulation of interleukin-12 synthesis in human endothelial cells.
European Journal of Immunology 30 (2000) 2864-2870
51. Beier KC, Hutloff A, Dittrich AM, Heuck C, Rauch A, Büchner K, Ludwig B, Ochs HD, Mages HW, KroczeK RA.
Induction, binding specificity and function of human ICOS.
European Journal of Immunology 30 (2000) 3707-3717
52. Ebner S, Ratzinger G, Krösbacher B, Schmuth M, Weiss A, Reider D, KroczeK RA, Herold M, Heufler C, Fritsch P, Romani N.
Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4.
Journal of Immunology 166 (2001) 633-641
53. Henn V, Steinbach S, Büchner K, Presek P, KroczeK RA.
The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by co-expressed CD40.
Blood 98 (2001) 1047-1054
54. Gonzalo JA, Tian J, Delaney T, Corcoran J, Rottman JB, Lora J, Al-garawi A, KroczeK R, Gutierrez-Ramos JC, Coyle AJ.

ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses.
Nature Immunology 2 (2001) 597-604

55. Khayyamian S, Hutloff A, Büchner K, Gräfe M, Henn V, KroczeK RA, Mages HW.
ICOS-Ligand, expressed on human endothelial cells, co-stimulates Th1 and Th2 cytokine secretion by memory CD4⁺ T cells.
Proceedings of the National Academy of Sciences 99 (2002) 6198-6203
56. Dorner BG, Scheffold A, Rolph MS, Hüser MB, Kaufmann SHE, Radbruch A, Flesch IEA, KroczeK RA.
MIP-1 α , MIP-1 β , RANTES and ATAC/lymphotactin function together with IFN- γ as type 1 cytokines.
Proceedings of the National Academy of Sciences 99 (2002) 6181-6186
57. Ringers J, Haanstra KG, KroczeK RA, Kliem K, Kuhn EM, Wubben J, Ossevoort MA, Volk HD, Jonker M.
Blockade of CD40-CD154 at the time of donor-specific blood transfusion does not lead to prolonged kidney allograft survival in nonhuman primates.
Transplantation 73 (2002) 862-866
58. Witsch EJ, Peiser M, Hutloff A, Büchner K, Dorner BG, Jonuleit H, Mages HW, KroczeK RA.
ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells.
European Journal of Immunology 32 (2002) 2680-2686
59. Löhning M*, Hutloff A*, Kallinich T, Mages HW, Bonhagen K, Radbruch A, Hamelmann E, KroczeK RA.
Expression of ICOS *in vivo* defines CD4⁺ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10.
Journal of Experimental Medicine 197 (2003) 181-193
60. Grimbacher B*, Hutloff A*, Schlesier M, Glocker E, Warnatz K, Dräger R, Eibel H, Fischer B, Schäffer AA, Mages HW, Peter HH*, KroczeK RA*.
Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency.
Nature Immunology 4 (2003) 261-268
61. Dorner BG, Steinbach S, Hüser MB, KroczeK RA, Scheffold A.
Single-cell analysis of the murine chemokines MIP-1 α , MIP-1 β , RANTES and ATAC/lymphotactin by flow cytometry.
Journal of Immunological Methods 274 (2003) 83-91
62. Bonhagen K, Liesenfeld O, Stadercker MJ, Hutloff A, Erb K, Coyle AJ, Lipp M, KroczeK RA, Kamradt T.
ICOS⁺ Th cells produce distinct cytokines in different mucosal immune responses.

63. Büchner K, Henn V, Gräfe M, de Boer OJ, Becker AE, KroczeK RA.
CD40 ligand is selectively expressed on CD4⁺ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis.
Journal of Pathology 201 (2003) 288-295
64. Blaschke S, Middel P, Dorner BG, Blaschke V, Hummel KM, KroczeK RA, Reich K, Benoehr P, Koziolék M, Müller GA.
Expression of activation-Induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis.
Arthritis and Rheumatism 48 (2003) 1858-1872
65. Kallinich T, Muche MJ, Qin S, Sterry W, Audring H, KroczeK RA.
Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides.
Journal of Investigative Dermatology 121 (2003) 1045-1052
66. Dorner BG, Smith HRC, French AR, Kim S, Poursine-Laurent J, Beckman DL, Pingel JT, KroczeK RA, Yokoyama WM.
Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection.
Journal of Immunology 172 (2004) 3119-3131
67. Sato T, Kanai T, Watanabe M, Sakuraba A, Okamoto S, Nakai T, Okazawa A, Inoue N, Totsuka T, Yamazaki M, KroczeK RA, Fukushima T, Ishii H, Hibi T.
Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease.
Gastroenterology 126 (2004) 829-839
68. Vermeiren J, Ceuppens JL, Van Ghelue M, Witters P, Bullens D, Mages HW, KroczeK RA, Van Gool SW.
Human T cell activation by costimulatory signal-deficient allogeneic cells induces inducible costimulator-expressing anergic T cells with regulatory cell activity.
Journal of Immunology 172 (2004) 5371-5378
69. Beier KC, Hutloff A, Löhning M, Kallinich T, KroczeK RA, Hamelmann E.
Inducible costimulator-positive T cells are required for allergen-induced local B-cell infiltration and antigen-specific IgE production in lung tissue.
Journal of Allergy and Clinical Immunology 114 (2004) 775-782
70. KroczeK RA, Mages HW, Hutloff A.
Emerging paradigms of T-cell co-stimulation.
Current Opinion in Immunology 16 (2004) 321-327

71. Hutloff A, Büchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A, Dorner T, KroczeK RA.
Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus.
Arthritis & Rheumatism 50 (2004) 3211-3220
72. Kallinich T, Schmidt S, Hamelmann E, Fischer A, Qin S, Luttmann W, Virchow JC, KroczeK RA.
Chemokine-receptor expression on T cells in lung compartments of challenged asthmatic patients.
Clinical & Experimental Allergy 35 (2005) 26-33
73. KroczeK RA, Hamelmann E.
T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies.
Journal of Allergy and Clinical Immunology 116 (2005) 906-909
74. de Haij S, Woltman AM, Trouw LA, Bakker AC, Kamerling SW, van der Kooij SW, Chen L, KroczeK RA, Daha MR, van Kooten C.
Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1.
Kidney International 68 (2005) 2091-102
75. Bullens DMA, Swerdt AD, Dilissen E, Kasran A, KroczeK RA, Cadot P, Casaer P, Ceuppens JL.
House dust mite-specific T cells in healthy non-atopic children.
Clinical & Experimental Allergy 35 (2005) 1535-1541
76. Kallinich T, Beier KC, Galfand EW, KroczeK RA, Hamelmann E.
Co-stimulatory molecules as potential targets for therapeutic intervention in allergic airway disease.
Clinical & Experimental Allergy 35 (2005) 1521-1534
77. Janke M, Witsch EJ, Mages HW, Hutloff A, KroczeK RA.
Eminent role of ICOS costimulation for T cells interacting with plasmacytoid dendritic cells.
Immunology 118 (2006) 353-360
78. Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, Meraviglia S, Borsellino G, KroczeK RA, Mendola CL, Scotet E, Dieli F, Salerno A.
CXCR5 identifies a subset of V γ 9V δ 2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production.
Journal of Immunology 177 (2006) 5290-5295